Four-Cycle High-Dose Therapy With Hematopoietic Support for Metastatic Breast Cancer: No Improvement in Outcomes Compared With Single-Course High-Dose Therapy

Biology of Blood and Marrow Transplantation

Volumn 6, Issue 1, 2000, Pages 58-69

  Hu, Wendy W ^a   Negrin, Robert S ^a   Stockerl Goldstein, Keith ^a   Johnston, Laura J ^a   Shizuru, Judith A ^a   Wong, Ruby M ^a   Chao, Nelson J ^a,b   Long, Gwynn D ^a,b   Feiner, Robert H ^a,c   Blume, Karl G ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c KAISER PERMANENTE   (United States)

Author keywords

Hematopoietic cell support; High dose therapy; Metastatic breast cancer; Multiple cycle

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; MELPHALAN; MICAT PROTOCOL; MITOXANTRONE; PACLITAXEL; PHARMACEUTICAL VEHICLES AND ADDITIVES; THIOTEPA;

ADULT; ARTICLE; AUTOTRANSPLANTATION; BLOOD TRANSFUSION; BREAST TUMOR; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; SURVIVAL RATE; TIME;

ADJUVANTS, PHARMACEUTIC; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; BREAST NEOPLASMS; CARMUSTINE; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; MELPHALAN; MIDDLE AGED; MITOXANTRONE; PACLITAXEL; SURVIVAL RATE; THIOTEPA; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0033630691     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1083-8791(00)70053-X     Document Type: Article

References (57)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1998. CA Cancer J Clin. 1998;48:3.
2. Bonadonna G, Valagussa P. Primary chemotherapy in operable breast cancer. Semin Oncol. 1996;23:464.
3. Colleoni M, Coates A, Pagani O, Goldhirsch A. Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question? Cancer Treat Rev. 1998;24:15.
4. Diab SG, Hilsenbeck SG, de Moor C, et al. Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol. 1998;16:1655.
5. Cody HS III. Sentinel lymph node mapping in breast cancer. Oncology. 1999;13:25.
6. Hayes DF, Henderson IC, Shapiro CL. Treatment of metastatic breast cancer: present and future prospects. Semin Oncol. 1995;22:5.
7. Peters WP, Baynes RD. Autologous hematopoietic cell transplantation for breast cancer. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. Malden, MA: Blackwell Science; 1999:1029.
8. Chlebowski RT, Lillington LM. A decade of breast cancer clinical investigation: results as reported in the Program/Proceedings of the American Society of Clinical Oncology. J Clin Oncol. 1994; 12:1789.
9. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870.
10. Rahman ZU, Frye DK, Buzdar AU, et al. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997;15:3171.
11. Coldman AJ, Goldie JH. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol. 1987;14:29.
12. Skipper H. Dose intensity versus total dose of chemotherapy: an experimental basis. In: DeVita VJ, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: JB Lippincott; 1993:43.
13. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253.
14. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90:1205.
15. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA, eds. Important Advances in Oncology. Philadelphia: JB Lippincott; 1988:121.
16. Gisselbrecht C. Chemotherapy dose intensity facilitated by use of lenograstim: implications for quality of life and survival. Eur J Cancer. 1994;30A(suppl 3):S30.
17. Lamar RE, Greco FA, Johnson DH, Murphy PB, Hainsworth JD. High-dose, brief duration, multiagent chemotherapy for metastatic breast cancer. Cancer. 1994;73:1842-1848.
18. Honkoop AH, Hoekman K, Wagstaff J, et al. Dose-intensive chemotherapy with doxorubicin, cyclophosphamide and GM-CSF fails to improve survival of metastatic breast cancer patients. Ann Oncol. 1996;7:35.
19. Hryniuk W, Frei R III, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol. 1998;16:3137.
20. Crown J, Kritz A, Vahdat L, et al. Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer J Clin Oncol. 1993;11:1144.
21. Long GD, Negrin RS, Hoyle CF, et al. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies. Cancer 1995;76:860.
22. Ghalie R, Williams SF, Valentino LA, et al. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant. 1995;1:40.
23. Patrone F, Ballestrero A, Ferrando F, et al. Four-step high-dose sequential chemotherapy with double hematopoietic progenitor-cell rescue for metastatic breast cancer. J Clin Oncol. 1995; 13:840.
24. Rodenhuis S, Westermann A, Holtkamp MJ, et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol. 1996;14:1473.
25. Shapiro CL, Ayash L, Webb IJ, et al. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients. J Clin Oncol. 1997;15:674.
26. Schilder RJ, Shea TC. Multiple cycles of high-dose chemotherapy for ovarian cancer. Semin Oncol. 1998;25:349.
27. Hu WW, Long GD, Stockerl-Goldstein KE, et al. A feasibility study of multiple cycle high dose therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. Clin Cancer Res. 1999;5:3411.
28. American Joint Committee on Cancer. In: Beahrs OH, Henson DE, Hutter DVP, Myers M, eds. Manual for Staging of Cancer. 3rd ed. Philadelphia: JB Lippincott; 1988.
29. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Pearlman ES, Macdonald JS. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst. 1991;83:920.
30. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132.
31. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol. 1995;13:1323.
32. Peters WP. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: yes. Important Adv Oncol. 1995;215.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
34. Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment. Bone Marrows Transplant. 1997;20:1063.
35. Wilczynski SW, Erasmus JJ, Petros WP, Vredenburgh JJ, Folz RJ. Delayed pulmonary toxicity syndrome following high-dose chemotherapy and bone marrow transplantation for breast cancer. Am J Respir Crit Care Med. 1998;157:565.
36. Shea T, Graham M, Bernard S, et al. A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer. Samin Oncol. 1995;22:80.
37. Ford C, Spitzer G, Reilly W, Adkins D. A phase II study of repetitive cycles of dose-intense carboplatin plus paclitaxel chemotherapy and peripheral blood stem cells in metastatic breast cancer. Semin Oncol. 1997;24(suppl):S17.
38. vonSchilling C, Herrmann F. Dose-intensified treatment of breast cancer: current results. J Molec A Med. 1995;73:611.
39. Vahdat L, Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer. Curr Opin Hematol. 1997;4:381.
40. Demirer T, Buckner CD, Lilleby K, et al. Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease. Cancer. 1994;74:715.
41. Ayash LJ, Elias A, Schwartz G, et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol. 1996;14:2984.
42. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995;13:2483.
43. Hortobagyi GN, Bodey GP, Buzdar AU, et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987;5:354.
44. Yeung AW, Pang YK, Tsang YC, Wong SW. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group. Cancer. 1994;73:1960.
45. Meisenberg BR, Miller WE, McMillan R. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC). Bone Marrow Transplant. 1996;18:1087.
46. Bitran JD, Samuels B, Klein L, et al. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transplant. 1996;17:157.
47. Lotz JP, Bouleuc C, Andre T, et al. Tandem high-dose chemotherapy with ifosfamide, carboplatin, and teniposide with autologous bone marrow transplantation for the treatment of poor prognosis common epithelial ovarian carcinoma. Cancer. 1996;77:2550.
48. Haas R, Schmid H, Hahn U, et al. Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective adjuvant treatment for high-risk primary breast cancer. Eur J Cancer. 1997;33:372.
49. Hohaus S, Wallwiener D, Martin S, et al. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer. Semin Oncol. 1998;25:7.
50. Honkoop AH, van der Wall E, Feller N, et al. Multiple cycles of high-dose doxorubicin and cyclophosphamide with G-CSF mobilized peripheral blood progenitor cell support in patients with metastatic breast cancer. Ann Oncol. 1997;8:957.
51. Huober J, Schneeweiss A, Hohaus S, et al. Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer. J Cancer Res Clin Oncol. 1998;124:690.
52. Gianni A, Siena S, Bregna M, Di Nicola M, Orefice S. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol. 1997;15:2312.
53. Viens P, Gravis G, Genre D, et al. High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer. Bone Marrows Transplant. 1997;20:199.
54. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290.
55. Hudis C, Seidman A, Baselga J, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol. 1999;17:93.
56. Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998;16:3439.
57. Frei E III, Elias A, Wheeler C, Richardson P, Hryniuk W. The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity. Clin Cancer Res. 1998;4:2027.